NCT06176560View on ClinicalTrials.gov

Phase III Multicentre Trial of Oral Mesalazine in Patients With Mild to Moderate Ulcerative Colitis.

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

376

Participants

Timeline

Start Date

March 31, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions
Colitis, Ulcerative
Interventions
DRUG

Mesalazine

Oral Formulation

Sponsors

Lead Sponsor

Faes Farma, S.A.
All Listed Sponsors
lead

Faes Farma, S.A.

INDUSTRY

NCT06176560 - Phase III Multicentre Trial of Oral Mesalazine in Patients With Mild to Moderate Ulcerative Colitis. | Biotech Hunter | Biotech Hunter